|1.||Zurek, Agnieszka A: 2 articles (04/2012 - 11/2010)|
|2.||Orser, Beverley A: 2 articles (04/2012 - 11/2010)|
|3.||Atack, J R: 2 articles (04/2000 - 01/2000)|
|4.||Ganguly, Milan: 1 article (10/2015)|
|5.||Stefanovic, Bojana: 1 article (10/2015)|
|6.||Chaudhuri, Joydeep: 1 article (10/2015)|
|7.||Corbett, Dale: 1 article (10/2015)|
|8.||Lake, Evelyn M R: 1 article (10/2015)|
|9.||Janik, Rafal: 1 article (10/2015)|
|10.||Stanisz, Greg J: 1 article (10/2015)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2000 - "Quantitative studies demonstrated that the number of [3H]L-655,708 binding sites is well preserved in Alzheimer's disease with only a moderate reduction (25-30%) in the CA1 subfield and entorhinal cortex. "
01/01/2000 - "The anatomical localization and pharmacology of alpha5 subunit-containing GABA type-A receptors in the human hippocampal formation of Alzheimer's disease patients were studied with an alpha5 receptor selective ligand, [3H]L-655,708 and compared to age-matched human controls. "
11/01/2006 - "When administered in a formulation specifically designed to achieve relatively constant plasma drug concentrations, and therefore maintain selective occupancy of alpha5- compared to alpha1-, alpha2- and alpha3-containing receptors (75+/-4% versus 22+/-10%, respectively), L-655,708 did not alter the dose of pentylenetetrazole required to induce seizures, indicating that the inverse agonist effects of L-655,708 at the alpha5 subtype are not associated with a proconvulsant liability. "
04/01/2000 - "However, in the hippocampus there was a significant, albeit modest, effect of treatment on the B(max) of [3H]MK-801 binding and the B(max) and K(D) of [3H]L-655,708 binding, i.e., PTZ-treated rats had fewer [3H]MK-801 and [3H]L-655,708 binding sites (NMDA and alpha5-containing GABA(A) receptors, respectively), but, these reductions were significant only in the relatively seizure-insensitive hooded Lister strain. "
|3.||Memory Disorders (Memory Loss)
04/01/2012 - "To determine whether inhibition of α5GABA(A) receptors reverses memory deficits, we treated a subset of mice with L-655,708 (0.35 mg/kg or 0.7 mg/kg) 23.5 hours after isoflurane and 30 minutes before behavioral training. "
11/01/2010 - "L-655,708 prevented memory deficit, suggesting that an isoflurane interaction at α5GABAA receptors contributes to memory impairment during the early postanesthesia period."
11/01/2010 - "The α5GABAA receptor inverse agonist, L-655,708, completely prevented memory deficits without changing the immobilizing dose of isoflurane. "
|2.||gamma-Aminobutyric Acid (GABA)
|3.||Dizocilpine Maleate (Dizocilpine)
|5.||GABA-A Receptors (GABA(A) Receptor)